Go to body Contents

EuDx™-MDR TB Detection Kit

  • Payment
    L/C(sight) , T/T
  • MOQ
    100 Set
  • Supply Ability
    500 Set per Month
  • Country of sale
    Asia, Africa
    • FOB

      Depend on quantity


  • Brand
  • origin
    Republic of Korea
  • Size(Capacity)
    1box 48tests
EuDx™-MDR TB Detection Kit
EuDx™-MDR TB Detection Kit (Multidrug-resistant TB, MDR TB)
diagnosis reagent swiftly analyzes the presence or absence
of mutations of rpoB, katG, inhA genes, which are the causation
genes of drug-resistance, in the genes IS6110, rpoB, RIF,
and INH through PCR. EuDx™-MDR TB Detection Kit (Multidrug-resistant TB, MDR TB)
is an In Vitro Diagnostic medical device aimed to aid in the diagnosis of TB pathogen infections and the determination of the drug-resistance of such TB pathogens
in suspected patients.

1) High Responsiveness and Specificity
- MTB and MDR TB → TB (IS6110) + 6 types of mutations 
- Simultaneous gene testing (Multiplex PCR)
- Fusion of various PCR technology (Real-time PCR + MGB TaqMan Probe Assay)

2) Minimizes pollution and Provides credible data
- 3 step PCR One tube test (prevents cross-pollution) 
- provides credible results through Internal control (IC) 

3) Increased patient satisfaction through swift diagnosis (85 minutes required)
- reduction of inspection time through simultaneous detection of TB and multidrug-resistant bacteria and increased possibility of early diagnosis and treatment

Currently, products sold for the diagnosis of drug-resistant TB can be summarized into three types. The product developed by LG Life Sciences and Hain Lifescience in Germany, currently holding the largest domestic market share, first extracts the DNA from the sample and amplifies the mutations of rpoB, katG, inhA genes, which are the causation genes of drug-resistance in the pathogens, through PCR. The resulting product then goes through hybridization with a membrane combined with a probe in order to check for mutations, but this process has a disadvantage - diagnosis takes 3-4 hours to complete. The second utilizes melting analysis and PCR developed by Seegene, and this analysis takes around 3 hours, but its share in the domestic market is negligible. Lastly, there is the Xpert RIF product developed by Cepheid, and this is the most popular product internationally. This product prioritizes analyzing small numbers of samples instead of large amounts, and it has a disadvantage in that it only checks for resistance towards Rifampicin in addition to being expensive. The product developed at Eudipia has a short diagnosis time of 90 minutes and it tests for both Rifampicin and Isoniazid simultaneously. No other comparable product has been manufactured thus far.
Product Composition
- 2X qPCR Premix
- 4X Reaction Mixture
(Primer/Probe + 
Internal Control)
- Positive Control DNA
- Nuclease Free Water
Product Specification
-1box 48tests


This supplier supports payments for offline orders
  • Telegraphic Transfer : T/T
  • Letter of Credit : L/C(sight)
Contact Payment Manager
  • Name : In Soo Kim
  • Tel : 82-07088902101
  • Email : info@eudipia.com


Shipping from : Republic of Korea
  • 194-41 Osongsaengmyeong 1-ro Osong-eup Heungdeok-gu, Cheongju-si, Chungcheongbuk-do Korea (28160)
Can't find a valid Shipping method for supplier account. Please contact the pertaining representative for detailed information.
EuDiPia Co. Ltd.

EuDiPia Co. Ltd.

www.eudipia.com Seller_Mail
  • The person in charge

    In Soo Kim
  • Telephone

  • Fax

  • Address

    194-41 Osongsaengmyeong 1-ro Osong-eup Heungdeok-gu, Cheongju-si, Chungcheongbuk-do Korea (28160)
Eudipia Co., Ltd. is a professional diagnostics company mainly providing molecular diagnosis services. We started with the diagnosis of tuberculosis and we plan to expand our diagnostic products to various fields. Eudipia Co., Ltd. was established with the goal of becoming the absolute best in the world in the diagnosis of tuberculosis. Since then we plan to expand our diagnostics to the fields of respiratory diseases and early cancer diagnosis. We named our company Eudipia in the hope to create an utopia through diagnosis. Furthermore, Swift and precise Fully Automated POCT system development for improved user convenience is currently in development, and diagnostics for respiratory viruses, MDR TB, venereal diseases, dengue, malaria, etc. are set to be released in 2017. Next, Eupidia Co., Ltd. plans to branch out into the world by establishing contracts with dealers and distributors through discovery of transaction lines country by country.
  • Business Type :
  • Main Product :
    EuDx™-MTB Detection Kit, MTB One-tube Nested Multiplex real-time PCR
  • Established :
  • Total Annual Revenue :
    6 million to 10 billion (KRW)
  • Total Employees :
    11~50 people


0 / 4000

질문이 없습니다.


At least 10~1000 characters.

0/ 1000


  • No Items
supplier level
EuDiPia Co. Ltd. Seller's Store
Seller's Store url
  • Response Level
      41% ~ 50%
  • Supplier Level
      1 million to 10 billion(KRW)
  • Transaction Level
      less than 5
  • EuDx™-MTB Detection Kit
  • EuDx™-ufPCR System[ultra fast system]
  • EuDx™-PN MLC Detection Kit